

ABSTRACT OF THE DISCLOSURE

Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having
5 improved bioavailability, and methods of using these compositions for inhibiting the
replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection.
These compositions include co-solvent systems, lipid based systems , solid dispersions
and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one
pharmaceutically acceptable amine and optionally one or more additional ingredients.

10

15

20

25